Avoiding bias and incorrect confidence interval coverage in prescription drug labeling

Abstract

These statistical properties may have important and undesirable regulatory and public health implications. We discuss an alternative approach to include results in labeling for a selected set of reliably ascertained, clinically important endpoints whether or not there is evidence of a treatment effect.